Breakout Stocks Corona Virus Stocks Top Mining Stocks
These shares are up 400% in 60 days , soaring to a 52 week high of $1.05 before consolidating . In addition,the company has raised $1.5 through warrant and option exercise on its meteoric run .
We look for a BREAKOUT above the $1.05 resistance level before the rally in these shares continues.We urge all serious investors to immediately place these shares on their BUY LIST
New Highs – MLSS NASDAQ – Breakout Territory – Should You Buy Today ?
Ontario–(Newsfile Corp. – January 29, 2021) – Therma Bright Inc. (TSXV: THRM) (OTC Pink: THRBF) (FSE: JNX), a progressive medical device technology company, is pleased to announce that in the past month, investors have exercised a total of 7,582,500 warrants and options to add $1,171,875 to the Company’s treasury. With the addition of the $300,000, as previously reported in the press release on December 24th, 2020, the Company has added a total of $1,471,875 to the Company’s treasury through the exercise of warrants and options in the last month.
GameStop – GME NYSE – Shorters To Scramble For Their Lives – Rome Burns While Nero Plays
These funds will be used to advance the development of the Company’s COVID-19 saliva-based rapid antigen test, SCV2, and for general working capital.About Therma Bright Inc.Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company’s initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare.
Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.Therma Bright Inc. trades on the TSXV: THRM, OTC MARKETS: THRBF, FRA:JNX. For more information visit: www.thermabright.com and www.coldsores.com
Therma Bright Reports Improved Accuracy For Its COVID-19 Rapid Saliva Antigen Test, CoviSafeTM, And Prepares For Prospective StudiesToronto, Ontario–(Newsfile Corp. – January 18, 2021) –
Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased to announce that the most recent results achieved with nanoComposix using banked human saliva samples and utilizing a CoviSafe™ prototype device indicate a test sensitivity of 86% and a specificity of 100% for Therma’s CoviSafe™ rapid antigen test for detecting SARS-CoV-2 virus in saliva.As previously reported on December 7, 2020 preliminary results achieved during the feasibility studies indicated a test sensitivity of 80% and a specificity of over 90% for Therma’s CoviSafe™.
Therma is pleased to have achieved improved sensitivity and specificity with the CoviSafe™ prototype device. This milestone now takes Therma Bright to the prospective clinical study phase which will be followed by regulatory approval applications.Therma’s CoviSafe™ prototype test showed an 86% sensitivity for samples with an RT_PCR Ct value below 30 and 100% sensitivity with Ct values of 25 or lower. Ct or Cycle Threshold value indicates the number of times or cycles, that a DNA/RNA sample needs to be amplified for it to be detected by an RT-PCR test – the gold standard test for detecting COVID-19.
The lower the Ct value, the higher the amount of viral RNA present in a sample, and the higher the Ct value, the lower the amount of viral RNA present in the sample. Current literature suggests that patients with Ct values below 30 are in the most infectious phase of the disease, so it is critical to identify these people as quickly as possible.
Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the TestToronto, Ontario–(Newsfile Corp. – January 25, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma Bright” or the “Company”), a progressive medical device technology company announces that it has taken 100% control of the research and development, regulatory, manufacturing and commercialization of its saliva-based rapid antigen test. As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test.
Therma Bright previously announced on November 4, 2020, that it would retain 50% of the revenue and profit from the sale of its rapid antigen test through Torion Biosciences Inc. (“Torion”). Therma Bright will no longer pursue that arrangement with Torion Biosciences Inc., with 100% of the future economic benefit now flowing directly to Therma Bright Inc.
In addition, Therma Bright will create a new trademark name for its saliva-based rapid antigen test, temporarily called SCV2, until a new name is protected.Corporate Updates:Therma Bright is pleased to report that it is in advanced discussions with potential testing sites in multiple locations across Canada as well as sites in the United States and the United Kingdom. Engaging in multiple locations will assist Therma Bright to achieve regulatory approvals in different jurisdictions such as CE in Europe and FDA and Health Canada approvals for North America. Such regulatory approvals will allow for the roll out of the commercial test for multiple markets in the future. Therma Bright will now procure sufficient test kits to be used in the prospective studies to occur in the month of February.Therma Bright is also in the process of identifying component suppliers to be used in the large-scale manufacturing of the SCV2 test and is identifying contract manufacturers to manufacture and assemble the final product.
Therma Bright also announces that it has negotiated debt settlements with arm’s length creditors. Pursuant to the debt settlement agreements, and subject to acceptance by the TSX Venture Exchange, the Company has agreed to settle aggregate outstanding debt of $65,250 in consideration for which it will issue an aggregate of 145,000 common shares at a deemed price of $0.45 per share. All shares issued in relation to these debt settlements are subject to a hold period expiring four months + one day after the date the shares are issued, in accordance with applicable securities laws and the policies of the TSX Venture Exchange.Rob Fia, CEO of
Therma Bright commented: “This is a big win for us and our shareholders as we maintain 100% of the sales and profits of SCV2. Since our last press release on January 18th, 2021, announcing 86% sensitivity and 100% specificity, we are pleased to have received significant interest from overseas facilities in the UK, the US and in addition to the Province of Ontario, other provinces in Canada. We will report back on the prospective study sites in the near future.”Therma Bright is not making any express or implied claims that its product, SCV2, has the ability to eliminate or cure COVID-19 (or SARS-CoV-2 virus).About SCV2SCV2 is a rapid antigen test developed as an at-home or point-of-need test that does not require lab instruments or specialized lab personnel to be performed. It can be administered by healthcare professionals or untrained users.
The test can help identify infected individuals in 15 minutes and is designed for at-home or point-of-need settings such as long-term care facilities, schools, or sporting events. Studies have shown that an efficient at-home antigen test would significantly reduce virus transmission, specifically by asymptomatic and pre-symptomatic patients. It would also allow individuals who receive negative tests to continue with their everyday activities, including work and school.SCV2 takes advantage of a lateral flow technology to detect the presence of the COVID-19 virus in saliva. When complete, the SCV2 rapid screening test could be ideal for use in a variety of scenarios, such as:As an at-home test and for monitoringTo identify if patients require further testing or treatment in a clinical settingTo verify if patients are ready for release from quarantineTo screen individuals prior to entering public venues such as airplanes, sporting events, religious gatherings, concerts and wedding events.
About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company’s initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated to relieve the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997
Certain statements in this news release constitute “forward-looking” statements. These statements relate to future events as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. Writer paid $2500 CA for this article The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.